101. Amlodipine in the treatment of Raynaud's phenomenon
- Author
-
I Gambini, Marco Rossi, N. Pitaro, G. Cini, Clodoveo Ferri, L. La Civita, and Dilia Giuggioli
- Subjects
medicine.medical_specialty ,business.industry ,Antagonist ,chemistry.chemical_element ,Mean age ,Calcium ,Crossover study ,Raynaud's phenomenon ,Rheumatology ,Underlying disease ,chemistry ,Internal medicine ,medicine ,Amlodipine ,Pharmacology (medical) ,In patient ,business ,medicine.drug - Abstract
Treatment with calcium antagonists has been shown to be beneficial in patients with primary and secondary Raynaud’s phenomenon. A double-blind placebo-controlled crossover trial was performed to assess the efficacy of amlodipine, a new long-acting calcium antagonist, in patients with Raynaud’s phenomenon without underlying disease. 20 of the 24 patients enrolled (20 women and 4 men, mean age 45 years) completed the trial.
- Published
- 1993